Meningococcal serogroup B vaccine in Italy: State-of-art, organizational aspects and perspectives

Journal of Preventive Medicine and Hygiene

Volumn 56, Issue 3, 2015, Pages E125-E132

  Signorelli, C ^a   Chiesa, V ^a   Odone, A ^a  

^a UNIVERSITY OF PARMA   (Italy)

Author keywords

Meningococcal diseases; Meningococcal serogroup B vaccine; Regional immunization schedules

Indexed keywords

MENINGOCOCCUS VACCINE;

ACTIVE IMMUNIZATION; BACTERIAL GENOME; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; HEALTH EDUCATION; HUMAN; IMMUNIZATION; ITALY; MENINGOCOCCEMIA; MENINGOCOCCOSIS; PREVENTIVE HEALTH SERVICE; REVIEW; SERUM BACTERICIDAL ANTIBODY ASSAY;

EID: 84949555424     PISSN: 11212233     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. World Health Organization (2011). Weekly epidemiological record. Meningococcal vaccines position paper. Available: http://www.who.int/wer/en/Accessed: May 2015.
2. Brigham KS, Sandora TJ. Neisseria meningitidis: epidemiology, treatment and prevention in adolescents. Current opinion in pediatrics. 2009;21:437-43.
3. Stein-Zamir C, Shoob H, Sokolov I, et al. The clinical features and long-term sequelae of invasive meningococcal disease in children. Pediatr Infect Dis J 2014;33:777-9.
4. Harrison OB, Brueggemann AB, Caugant DA, et al. Molecular typing methods for outbreak detection and surveillance of invasive disease caused by Neisseria meningitidis, Haemophilus influenzae and Streptococcus pneumoniae, a review. Microbiology (Reading, England). 2011;157(Pt 8):2181-95.
5. Bishai DM, Champion C, Steele ME, et al. Product development partnerships hit their stride: lessons from developing a meningitis vaccine for Africa. Health Affairs (Project Hope) 2011;30:1058-64.
6. Xie O, Pollard AJ, Mueller JE, et al. Emergence of serogroup X meningococcal disease in Africa: need for a vaccine. Vaccine 2013;31:2852-61.
7. World Health Organization (2015). Weekly epidemiological record. Available: http://www.who.int/wer/en/Accessed: May 2015.
8. European Centre for Disease Prevention and Control. Surveillance of invasive bacterial diseases in Europe, 2012. Stockholm: ECDC; 2015.
9. Jafri RZ, Ali A, Messonnier NE, Tevi-Benissan C, et al. Global epidemiology of invasive meningococcal disease. Popul Health Metr 2013;11:17.
10. World Health Organization. Meningococcal meningitis. Available: http://www.who.int/mediacentre/factsheets/fs141/en/. Accessed: May 2015.
11. European Centre for Disease Prevention and Control. Annual epidemiological report 2014 - Vaccine-preventable diseases - invasive bacterial diseases. Stockholm: ECDC 2015.
12. Racloz VN, Luiz SJ. The elusive meningococcal meningitis serogroup: a systematic review of serogroup B epidemiology. BMC Infect Dis 2010;10:175.
13. Food and Drug Administration (FDA). First vaccine approved by FDA to prevent serogroup B Meningococcal disease. 2014.
14. Giuliani MM, Adu-Bobie J, Comanducci M, et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci USA 2006;103:10834-9.
15. Martin NG, Snape MD. A multicomponent serogroup B meningococcal vaccine is licensed for use in Europe: what do we know, and what are we yet to learn? Expert Rev Vaccines. 2013;12:837-58.
16. Rappuoli R. Reverse vaccinology, a genome-based approach to vaccine development. Vaccine 2001;19:2688-91.
17. Kelly DF, Rappuoli R. Reverse vaccinology and vaccines for serogroup B Neisseria meningitidis. Adv Exp Med Biol 2005;568:217-23.
18. Pizza M, Scarlato V, Masignani V, et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science (New York, NY). 2000;287:1816-20.
19. Shea MW. The long road to an effective vaccine for meningococcus Group B (MenB). Ann Med Surg (Lond) 2013;2:53-6.
20. European Medicines Agency (2013). Bexsero: Authorization details. Available: http://www.ema.europa.eu/ema/index. jsp?curl=pages/medicines/human/medicines/002333human-med-001614.jsp&mid=WC0b01ac058001d124. Accessed: May 2015.
21. Food and Drug Administration (FDA). TRUMENBA. Available: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm421020.htm Accessed: June 2015
22. Gossger N, Snape MD, Yu LM, et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA 2012;307:573-82.
23. Prymula R, Esposito S, Zuccotti GV, et al. A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I). Hum Vaccin Immunother 2014;10:1993-2004.
24. Santolaya ME, O'Ryan ML, Valenzuela MT, et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet 2012;379:617-24.
25. Vesikari T, Esposito S, Prymula R, et al. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet. 2013;381:825-35.
26. ® meningococcal B vaccine in the UK. 21st March 2014. Available: https://http://www.gov. uk/government/publications/meningococcal-b-vaccine-jcvi-position-statement Accessed: May 2015.
27. ®. Available: http://www.hcsp.fr/explore.cgi/avisrapportsdomaine?clefr=386 Accessed: May 2015.
28. ®. Robert Koch Institute. 9 diciembre 2013. Available: http://www.rki.de/EN/Content/Prevention/VaccinationrecommandationsSTIKO-statement-Men-SgB.html Accessed: May 2015.
29. Centre for Disease Prevention and Control (2014). Meningococcal Serogroup B Vaccine and Outbreaks. Available: http://www.cdc.gov/meningococcal/outbreaks/vaccine-serogroupb.html. Accessed: May 2015.
30. Meningococcal B Pilot Project Task Group. National Advisory Committee on Immunization (2014). Public Health Agency in Canada. The recommended use of the multicomponent meningo-coccal B (4CMenB) vaccine in Canada: common guidance statement. Available: http://www.phac-aspc.gc.ca/naci-ccni/mening-4cmenb-exec-resum-eng.php Accessed: May 2015.
31. Istituto Superiore di Sanità (ISS). Dati di sorveglianza delle malattie batteriche invasive aggiornati al 23 marzo 2015.
32. Istituto Superiore di Sanità (ISS). Rapporti della sorveglianza delle malattie batteriche invasive dell'Istituto Superiore di Sanità. Available: http://www.iss.it/mabi/index. php?lang=1&id=5&tipo=16 Accessed: June 2015.
33. Istituto Superiore di Sanità (ISS). Vaccinazione anti-meningococco B: dati ed evidenze disponibili per l'introduzione in nuovi nati e adolescenti. 2015.
34. Piano Nazionale Prevenzione Vaccinale (PNPV) 2012-2014. Ministero della Salute.
35. Bonanni P, Azzari C, Castiglia P, et al. [The 2014 lifetime immunization schedule approved by the Italian scientific societies]. Epidemiologia e Prevenzione 2014;38(6 Suppl 2):131-46.
36. Delibera Provinciale. Bolzano (2013). Il calendario vaccinale per l'Alto Adige.
37. Bollettino Ufficiale della Regione Autonoma Trentino-Alto Adige. 21 maggio 2013 Supplemento n. 1.
38. Deliberazione giunta regionale. Commissione Regionale Vaccini. Modifica Calendario Regionale per la vita 2012 - DGR 241/2013. Approvazione nuovo Calendario Vaccinale per la vita 2014. Deliberazione n. 958 del 20-05-2014. Regione Puglia.
39. Deliberazione giunta regionale. Calendario vaccinale della Regione Toscana e direttive in materia di vaccinazioni. Aggiornamento al 2014. Delibera N 823 del 06-10-2014. Regione Toscana.
40. Calendario vaccinale della Regione Toscana e direttive in materia di vaccinazioni. Aggiornamento al 2014.
41. Deliberazione Giunta Regionale. Approvazione del documento tecnico-scientifico dal titolo "Programma di campagna vaccinale per la prevenzione primaria della malattia invasiva da meningococco di gruppo B". Regione Basilicata.
42. Gazzetta Ufficiale della Regione Siciliana. Parte I. Palermo 30 gennaio 2015.
43. Assessorato Regionale della Salute. "Calendario Vaccinale per la Vita" Modifica ed integrazione del Calendario Vaccinale Regionale. Regione Sicilia.
44. Bollettino Ufficiale Regione Liguria: Parte II 21.01.2015. Aggiornamento Piano Regionale Prevenzione Vaccinale.
45. Bollettino Ufficiale Regione Veneto: n. 89 del 12 settembre 2014.
46. Offerta vaccinale per l'infanzia ed adolescenza della Regione Friuli Venezia Giulia.
47. Deliberazione Giunta Regionale. Offerta vaccinale regionale: Vaccinazioni raccomandate per i gruppi a rischio. delibera n. 2535 del 18 dicembre 2014. Regione Fruli Venezia Giulia.
48. DCA n. 43 del 21 Maggio 2015. Oggetto: P. O. 2013-2015. Programma 11 - Sanità pubblica. Az. 11.2.1 e 11.2.2 "Miglioramento della copertura vaccinale specifica nelle diverse face d'età". Regione Calabria.
49. Bonanni P, Ferro A, Guerra R, et al. Vaccine coverage in Italy and assessment of the 2012-2014 National Immunization Prevention Plan. Epidemiol Prev 2015;39(Suppl 1):146-58.
50. Odone A, Ferrari A, Spagnoli F, et al. Effectiveness of interventions that apply new media to improve vaccine uptake and vaccine coverage. Hum Vaccin Immunother 2015;11:72-82.
51. Centro Nazionale Studi Investimenti Sociali (CENSIS). La prevenzione della meningite da meningococco B: la vaccinazione contro il Meningococco B secondo i genitori italiani. Sintesi dei risultati. Roma, aprile 2015.
52. Odone A, Fara GM, Giammaco G, et al. The future of immunization policies in Italy and in the European Union: the Declaration of Erice. Hum Vaccin Immunother 2015;11:1268-71.
53. Signorelli C. [Vaccines: building on scientific excellence and dispelling false myths]. Epidemiol Prev 2015;39 (4).
54. Centre for Disease Prevention and Control (2005). Prevention and Control of Meningococcal Disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Available: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5407a1.htm Accessed: June 2015
55. Tirani M, Meregaglia M, Melegaro A. Health and economic outcomes of introducing the new MenB vaccine (Bexsero) into the Italian routine infant immunisation programme. PloS One 2015;10:e0123383.
56. Ferro A, Odone A, Siddu A, et al. Monitoring the web to support vaccine coverage: results of two years of the portal VaccinarSì. Epidemiol Prev 2015;39:88-93.
57. Odone A, Chiesa V, Ciorba V, et al. Influenza and immunization: a quantitative study of media coverage in the season of the "Fluad case". Epidemiol Prev 2015;39:139-45.
58. Signorelli C, Odone A, Pezzetti F, et al. Human Papillomavirus infection and vaccination: knowledge and attitudes of Italian general practitioners. Epidemiol Prev 2014;38:88-92.
59. Signorelli C, Odone A, Conversano M, et al. Deaths after Fluad flu vaccine and the epidemic of panic in Italy. BMJ 2015;350:h116.